Sumitomo Mitsui Trust Holdings Inc. lowered its stake in Hologic, Inc. (NASDAQ:HOLX – Free Report) by 30.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 747,568 shares of the medical equipment provider’s stock after selling 332,819 shares during the period. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Hologic were worth $60,329,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in HOLX. Macquarie Group Ltd. boosted its holdings in shares of Hologic by 227.2% during the 2nd quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock valued at $435,485,000 after buying an additional 4,363,687 shares in the last quarter. Norges Bank bought a new stake in shares of Hologic during the 4th quarter valued at $175,900,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Hologic by 110.6% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,896,174 shares of the medical equipment provider’s stock valued at $145,664,000 after buying an additional 995,854 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Hologic by 21.3% during the 4th quarter. Victory Capital Management Inc. now owns 5,174,355 shares of the medical equipment provider’s stock valued at $387,093,000 after buying an additional 907,874 shares in the last quarter. Finally, Prudential Financial Inc. boosted its holdings in shares of Hologic by 246.0% during the 1st quarter. Prudential Financial Inc. now owns 920,718 shares of the medical equipment provider’s stock valued at $70,730,000 after buying an additional 654,628 shares in the last quarter. Institutional investors own 93.29% of the company’s stock.
Wall Street Analyst Weigh In
A number of analysts have recently commented on HOLX shares. StockNews.com started coverage on shares of Hologic in a report on Thursday, May 18th. They set a “buy” rating on the stock. Citigroup boosted their target price on shares of Hologic from $85.00 to $90.00 in a report on Tuesday, May 2nd. Needham & Company LLC raised Hologic from a “hold” rating to a “buy” rating and set a $95.00 price target for the company in a research report on Friday. Mizuho lifted their price target on Hologic from $92.00 to $95.00 in a research report on Tuesday, May 2nd. Finally, JPMorgan Chase & Co. lifted their price target on Hologic from $95.00 to $105.00 in a research report on Tuesday, May 2nd. Eight research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Hologic currently has an average rating of “Moderate Buy” and a consensus target price of $86.64.
Hologic Price Performance
Hologic (NASDAQ:HOLX – Get Free Report) last released its quarterly earnings results on Monday, May 1st. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.18. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $957.53 million. Hologic had a return on equity of 19.39% and a net margin of 18.56%. The business’s quarterly revenue was down 28.5% compared to the same quarter last year. During the same period in the previous year, the company posted $2.07 EPS. On average, analysts expect that Hologic, Inc. will post 3.89 earnings per share for the current year.
Insider Buying and Selling at Hologic
In related news, Director Scott T. Garrett sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $79.72, for a total transaction of $797,200.00. Following the completion of the transaction, the director now directly owns 57,039 shares in the company, valued at approximately $4,547,149.08. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider Essex D. Mitchell sold 2,390 shares of the business’s stock in a transaction that occurred on Friday, May 5th. The stock was sold at an average price of $83.73, for a total transaction of $200,114.70. Following the completion of the transaction, the insider now directly owns 7,212 shares in the company, valued at approximately $603,860.76. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Scott T. Garrett sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $79.72, for a total value of $797,200.00. Following the transaction, the director now owns 57,039 shares of the company’s stock, valued at $4,547,149.08. The disclosure for this sale can be found here. Corporate insiders own 1.66% of the company’s stock.
Hologic Company Profile
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
Featured Articles
- Five stocks we like better than Hologic
- Is It Time To Take Another Bite Of Chewy, Inc?
- GreenPower Motor Company Shifts Into High Gear
- Is the Microsoft Deal Driving Applied Optoelectronics 300% Gain?
- Can Unity Software Sustain The Momentum?
- Nvidia Invested $50 million into This AI Drug Discovery Biotech
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX – Free Report).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.
